Merck Applauds the U.S. Department of Veterans Affairs (VA) for Broadening...
(Source: Merck & Co Inc) KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, applauds the U.S. Department of Veterans Affairs (VA) for broadening...
View ArticleMerck to Present New Findings from Chronic Hepatitis C Clinical Development...
(Source: Merck & Co Inc) KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the planned presentations of data from the...
View ArticleMerck Announces Results From Phase 3 Studies of ZEPATIER(TM) (Elbasvir and...
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from two Phase 3 clinical trials evaluating ZEPATIER™ (elbasvir and grazoprevir)...
View ArticleMerck Announces Results From Phase 3 Studies of ZEPATIER™ (Elbasvir and...
(Source: Merck & Co Inc) KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from two Phase 3...
View ArticleAbbVie Receives CHMP Positive Opinion for Eight-Week Treatment Option with...
- CHMP opinion brings AbbVie one step closer to approval of an eight-week regimen of VIEKIRAX + EXVIERA for previously untreated genotype 1b (GT1b) chronic hepatitis C virus (HCV) patients with minimal...
View ArticleMerck’s ZEPATIER™ (Elbasvir and Grazoprevir) Showed Superiority on Efficacy...
(Source: Merck & Co Inc) KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from C-EDGE...
View ArticleMerck Receives FDA Approval of ZEPATIER™ (elbasvir and grazoprevir) for the...
(Source: Merck & Co Inc) KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has...
View ArticleBristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for...
(Source: Bristol-Myers Squibb Company) BMS-663068 is the first investigational antiretroviral designed to prevent HIV attachment to and entry into CD4+ T cells FDA Breakthrough Designation recognizes...
View ArticleJanssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral,...
(Source: Johnson & Johnson) July 23, 2015 Janssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral, Once-Daily OLYSIO® (Simeprevir) in Combination with Sofosbuvir Filing Supported...
View ArticleJanssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral,...
TITUSVILLE, N.J., July 23, 2015 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced the submission of a supplemental New Drug Application (sNDA) to the...
View ArticleYour Story, Your HIV Wisdom™ Brings Together HIV Voices and Supports HIV...
(Source: Johnson & Johnson) Notable HIV Advocates Highlight Perspectives of People Living with or Affected by HIV to Leverage Shared Support and Self-Expression TITUSVILLE, N.J., September 8, 2015...
View ArticleYour Story, Your HIV Wisdom™ Brings Together HIV Voices and Supports HIV...
TITUSVILLE, N.J., Sept. 8, 2015 /PRNewswire/ -- Seeking and sharing information are important parts of the HIV journey – in fact, 80 percent of people living with HIV said they give advice or tell...
View ArticleU.S. FDA Approves PREZISTA® (darunavir) for Use in Pregnant Women with HIV...
(Source: Johnson & Johnson) Data shows PREZISTA is a safe and effective treatment option in pregnant women, with no reports of mother-to-child HIV transmission among women who continued therapy...
View ArticleEnanta Announces Data to be Presented on AbbVie’s MAVYRET™...
16 HCV abstracts to be presented including 12 data presentations on the safety and efficacy of MAVYRET MAVYRET is recommended in new AASLD guidelines as a first line treatment option for 8 weeks in...
View ArticleMerck Receives Approval of ZEPATIER™ (elbasvir/grazoprevir) in Canada for the...
(Source: Merck Canada Inc) 00f0678e-090a-4f9c-a736-8cbc159b1544.pdf News Release FOR IMMEDIATE RELEASE Media Contact: Annick Robinson (438) 837-2550 Investor Contact: Amy Klug (908) 740-1898 Merck...
View ArticleEnanta Announces New Data from AbbVie’s SURVEYOR-1 and SURVEYOR-2 Studies...
(Source: Enanta Pharmaceuticals Inc) 97-98 percent SVRachieved with eight weeks of ABT-493 and ABT-530 treatment ingenotypes 1, 2 or 3 HCV patients without cirrhosis in SURVEYOR 1 and 2 studies 100...
View ArticleU.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza...
(Source: Bristol-Myers Squibb Company) PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that Daklinza (daclatasvir, 60 mg), an NS5A replication complex...
View ArticleFDA approves Technivie for treatment of chronic hepatitis C genotype 4 (FDA -...
(Source: FDA - Food and Drug Administration) Release The U.S. Food and Drug Administration today approved Technivie (ombitasvir, paritaprevir and ritonavir) for use in combination with ribavirin for...
View ArticleEnanta Pharmaceuticals Announces Investigational Regimen Containing Enanta’s...
(Source: Enanta Pharmaceuticals Inc) Data from AbbVie’s SURVEYOR-I and SURVEYOR-II studies demonstrate high sustained virologic response rates at 12 weeks post-treatment (SVR 12 ) in non-cirrhotic...
View ArticleEight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic,...
(Source: AbbVie Inc) - 99 percent (n=105/106) of genotype 1 (GT1) chronic HCV-infected Japanese patients without cirrhosis achieved SVR[12] with 8 weeks of G/P - Japan has one of the highest rates of...
View Article